Filing summary
Issuer mismatch: The request identifies Accendra Health Inc., but the supplied Form 10-Q is for Owens & Minor, Inc. This summary covers the filing actually provided.
Business context and reporting period
Quarterly report for the three and six months ended June 30, 2016. Owens & Minor describes itself as a healthcare services company providing medical-product distribution, logistics and value-added services, plus clinical and procedural solutions. It reorganized reporting into Domestic, International and Clinical & Procedural Solutions (CPS) segments and recast prior-period segment results.
Financial performance
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $2,483.7m | $2,422.2m | $4,939.5m | $4,813.4m |
| Gross margin | $299.4m; 12.06% | $298.3m; 12.32% | $596.1m; 12.07% | $595.9m; 12.38% |
| Operating earnings | $52.1m | $47.9m | $97.0m | $88.8m |
| Net income | $27.7m | $24.2m | $51.9m | $43.2m |
| Diluted EPS | $0.45 | $0.39 | $0.83 | $0.69 |
| Operating cash flow | Not separately presented for the quarter | $42.6m | $246.8m |
Adjusted non-GAAP diluted EPS was $0.52 for Q2 and $1.02 year to date, versus $0.46 and $0.90 in the prior-year periods. The company attributes improved earnings primarily to revenue growth and transformation-related expense controls.
Financial condition and material changes
- Revenue increased 2.5% in Q2 and 2.6% year to date. Domestic revenue rose 2.9% and 3.0%, respectively; International revenue fell 4.6% and 8.6%; CPS revenue was down 0.6% in Q2 but up 4.1% year to date.
- Gross margin dollars were nearly flat year to date despite revenue growth, and gross margin rate declined 31 basis points. Management cited lower income from manufacturer price changes, the U.K. customer exit, and foreign-exchange effects.
- Distribution, selling and administrative expenses declined 1.6% in Q2 and 2.2% year to date, reflecting cost controls, lower fuel costs and operational efficiency.
- Operating cash flow was $42.6m, down from $246.8m. Management attributed the decline primarily to working-capital changes, including prior-year vendor-payment timing. Investing used $8.9m; financing used $58.2m. Cash declined $22.1m to $139.0m.
- At June 30, cash was $139.0m, current assets $1,974.8m and current liabilities $1,044.1m. Long-term debt, excluding current portion, was $567.0m. The company had $550m of senior notes due 2021 and 2024, no revolver borrowings, and $445m available under its $450m credit facility after letters of credit. Management reported covenant compliance.
- The company paid $32.0m in dividends and repurchased $20.8m of shares during the first half. Approximately $49.2m remained under the share-repurchase authorization.
Outlook, risks and unusual items
- Management expects the previously announced exit of a large Domestic customer to reduce revenue, gross margin and Domestic operating earnings in the second half of 2016. It provided no specific full-year numerical guidance in the supplied filing text.
- Q2 acquisition-related and exit/realignment charges totaled $6.8m; first-half charges were $17.2m. These included severance and costs related to organizational realignment and integration matters. Adjusted results exclude these charges.
- The company added Brexit as a risk factor, noting uncertainty about trade, legal and financial effects and possible adverse currency and economic impacts on its European operations.
- Other stated risks include customer concentration and retention, pricing and competitive pressure, supplier dependence, foreign-exchange exposure, healthcare regulation, information-system disruption or security breaches, and litigation and tax contingencies.
- Management said available cash and financing sources should be sufficient for expected needs, while noting that economic conditions could affect financing access and costs and customer or supplier performance. Disclosure controls were assessed as effective; no material legal-proceeding developments were reported.
Investor verification points
- Confirm the intended issuer: the supplied filing is Owens & Minor, not Accendra Health.
- Assess the expected timing and financial impact of the large-customer exit, especially on second-half revenue, gross margin and Domestic earnings.
- Examine the drivers and sustainability of the sharp year-over-year decline in operating cash flow and changes in working capital.
- Review recurring versus restructuring-related costs and the assumptions behind management’s adjusted non-GAAP measures.
- Monitor Brexit, currency movements, customer and supplier concentration, and covenant and liquidity headroom.